Your browser doesn't support javascript.
loading
In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types.
Matossian, M D; Chang, T; Wright, M K; Burks, H E; Elliott, S; Sabol, R A; Wathieu, H; Windsor, G O; Alzoubi, M S; King, C T; Bursavich, J B; Ham, A M; Savoie, J J; Nguyen, K; Baddoo, M; Flemington, E; Sirenko, O; Cromwell, E F; Hebert, K L; Lau, F; Izadpanah, R; Brown, H; Sinha, S; Zabaleta, J; Riker, A I; Moroz, K; Miele, L; Zea, A H; Ochoa, A; Bunnell, B A; Collins-Burow, B M; Martin, E C; Burow, M E.
Afiliação
  • Matossian MD; Department of Medicine, Section of Hematology & Medical Oncology, Tulane University School of Medicine, New Orleans, LA, USA.
  • Chang T; Department of Medicine, Section of Hematology & Medical Oncology, Tulane University School of Medicine, New Orleans, LA, USA.
  • Wright MK; Department of Medicine, Section of Hematology & Medical Oncology, Tulane University School of Medicine, New Orleans, LA, USA.
  • Burks HE; Department of Medicine, Section of Hematology & Medical Oncology, Tulane University School of Medicine, New Orleans, LA, USA.
  • Elliott S; Department of Medicine, Section of Hematology & Medical Oncology, Tulane University School of Medicine, New Orleans, LA, USA.
  • Sabol RA; Tulane Center for Stem Cell Research and Regenerative Medicine, New Orleans, LA, USA.
  • Wathieu H; Department of Medicine, Section of Hematology & Medical Oncology, Tulane University School of Medicine, New Orleans, LA, USA.
  • Windsor GO; Department of Medicine, Section of Hematology & Medical Oncology, Tulane University School of Medicine, New Orleans, LA, USA.
  • Alzoubi MS; Department of Medicine, Section of Hematology & Medical Oncology, Tulane University School of Medicine, New Orleans, LA, USA.
  • King CT; Department of Biological and Agricultural Engineering, Louisiana State University, Baton Rouge, LA, USA.
  • Bursavich JB; Department of Biological and Agricultural Engineering, Louisiana State University, Baton Rouge, LA, USA.
  • Ham AM; Department of Biological and Agricultural Engineering, Louisiana State University, Baton Rouge, LA, USA.
  • Savoie JJ; Department of Biological and Agricultural Engineering, Louisiana State University, Baton Rouge, LA, USA.
  • Nguyen K; Department of Medicine, Section of Hematology & Medical Oncology, Tulane University School of Medicine, New Orleans, LA, USA.
  • Baddoo M; Cancer Genetics Program, Tulane University School of Medicine, New Orleans, LA, USA.
  • Flemington E; Cancer Genetics Program, Tulane University School of Medicine, New Orleans, LA, USA.
  • Sirenko O; Molecular Devices LLC, San Jose, CA, USA.
  • Cromwell EF; Protein Fluidics Inc, Burlingame, CA, USA.
  • Hebert KL; Department of Medicine, Section of Hematology & Medical Oncology, Tulane University School of Medicine, New Orleans, LA, USA.
  • Lau F; Department of Surgery, Section of Plastic & Reconstructive Surgery, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
  • Izadpanah R; Tulane Cancer Center, New Orleans, LA, USA.
  • Brown H; Innogenomics Technologies LLC, New Orleans, LA, USA.
  • Sinha S; Innogenomics Technologies LLC, New Orleans, LA, USA.
  • Zabaleta J; Department of Pediatrics, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
  • Riker AI; Cancer Service Line, Anne Arundel Medical Center, Luminis Health, DeCesaris Cancer Institute, Annapolis, MD, USA.
  • Moroz K; Louisiana Cancer Research Center, Biospecimen Core, New Orleans, LA, USA.
  • Miele L; Department of Pathology, Tulane University School of Medicine, New Orleans, LA, USA.
  • Zea AH; Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
  • Ochoa A; Louisiana Cancer Research Center, Biospecimen Core, New Orleans, LA, USA.
  • Bunnell BA; Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
  • Collins-Burow BM; Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
  • Martin EC; Department of Microbiology, Immunology, and Genetics, University of North Texas Health Science Center, Fort Worth, TX, USA.
  • Burow ME; Department of Medicine, Section of Hematology & Medical Oncology, Tulane University School of Medicine, New Orleans, LA, USA.
Clin Transl Oncol ; 24(1): 127-144, 2022 Jan.
Article em En | MEDLINE | ID: mdl-34370182
ABSTRACT
Metaplastic breast carcinoma (MBC) is a rare breast cancer subtype with rapid growth, high rates of metastasis, recurrence and drug resistance, and diverse molecular and histological heterogeneity. Patient-derived xenografts (PDXs) provide a translational tool and physiologically relevant system to evaluate tumor biology of rare subtypes. Here, we provide an in-depth comprehensive characterization of a new PDX model for MBC, TU-BcX-4IC. TU-BcX-4IC is a clinically aggressive tumor exhibiting rapid growth in vivo, spontaneous metastases, and elevated levels of cell-free DNA and circulating tumor cell DNA. Relative chemosensitivity of primary cells derived from TU-BcX-4IC was performed using the National Cancer Institute (NCI) oncology drug set, crystal violet staining, and cytotoxic live/dead immunofluorescence stains in adherent and organoid culture conditions. We employed novel spheroid/organoid incubation methods (Pu·MA system) to demonstrate that TU-BcX-4IC is resistant to paclitaxel. An innovative physiologically relevant system using human adipose tissue was used to evaluate presence of cancer stem cell-like populations ex vivo. Tissue decellularization, cryogenic-scanning electron microscopy imaging and rheometry revealed consistent matrix architecture and stiffness were consistent despite serial transplantation. Matrix-associated gene pathways were essentially unchanged with serial passages, as determined by qPCR and RNA sequencing, suggesting utility of decellularized PDXs for in vitro screens. We determined type V collagen to be present throughout all serial passage of TU-BcX-4IC tumor, suggesting it is required for tumor maintenance and is a potential viable target for MBC. In this study we introduce an innovative and translational model system to study cell-matrix interactions in rare cancer types using higher passage PDX tissue.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias de Mama Triplo Negativas / Modelos Biológicos / Antineoplásicos Limite: Animals / Humans Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias de Mama Triplo Negativas / Modelos Biológicos / Antineoplásicos Limite: Animals / Humans Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos